Cart
sales@molnova.com
YIR-819
CAS No. 1883372-86-8
YIR-819( YIR819 )
Catalog No. M12922 CAS No. 1883372-86-8
YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameYIR-819
-
NoteResearch use only, not for human use.
-
Brief DescriptionYIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor.
-
DescriptionYIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM); A useful lead compound for the further development of HIV-1 entry inhibitors and could potentially be useful for co-administration with neutralizing antibodies for the treatment of HIV infection and AIDS.
-
In Vitro——
-
In Vivo——
-
SynonymsYIR819
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1883372-86-8
-
Formula Weight492.021
-
Molecular FormulaC23H34ClN7O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN1-(4-chlorophenyl)-N2-(1-(2-(2-guanidinoacetamido)ethyl)-1-azaspiro[5.5]undecan-4-yl)oxalamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ohashi N, et al. ChemMedChem. 2016 Apr 19;11(8):940-6.
molnova catalog
related products
-
Dolutegravir interme...
Dolutegravir intermediate-1 is a new synthetic Dolutegravir intermediate extracted from patent WO 2016125192 A2.
-
HIV-1 integrase inhi...
HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication .
-
KNI-1657
KNI-1657 (KNI1657) is a highly potent HIV-1 protease inhibitor (97% inhibition at 1 nM) with high sensitivity against lopinavir/ritonavir- or darunavir-resistant strains.
